Compare Archer-Daniels-Midland Co (ADM) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Archer-Daniels-Midland Co vs BioNano Genomics Inc — how do they compare? Archer-Daniels-Midland Co trades at $79.85 (market cap $37.69B), while BioNano Genomics Inc trades at $1.14 (market cap $13.08M). The key difference: Archer-Daniels-Midland Co is far larger — about 2881.5× BioNano Genomics Inc's market cap, and Archer-Daniels-Midland Co pays a 2.66% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ADM | BNGO | |
|---|---|---|
Market Cap | $37.69B | $13.08M |
Sector | Consumer Staples | Health |
52-Week High | $84.11 | $4.92 |
52-Week Low | $53.54 | $1.09 |
Enterprise Value | $47.72B | $15.69M |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADM trades at $78.20, up 1.84% recently, with a bullish technical signal from moving averages and a consensus analyst price target of $78.00. The company has beaten EPS estimates for three consecutive quarters, though revenue has declined from $101.6B in 2022 to $80.3B in 2025. Net cash flow improved to $1.58B in 2025, reversing negative trends from prior years, while the stock shows a P/E of 34.79 and P/S of 0.47, indicating mixed valuation signals.
Outlook is cautiously optimistic with strong cash flow and earnings beats, but risks include declining revenue margins and competitive pressures. The stock offers value characteristics with a low P/S ratio, yet investors face headwinds from narrowing profit margins and global trade volatility in agricultural markets.
BNGO trades at $1.14, down 0.87% on the day, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported Q1 2026 revenue of $28.51M and a net loss of $26.40M, though it beat EPS estimates. Recent news includes leadership changes, debt retirement, and growing adoption of its optical genome mapping technology. Valuation ratios appear low with a P/E of 0.03 and P/S of 0.3, but profitability remains negative.
Outlook is cautiously optimistic due to improving cash flow trends and analyst support, but significant risks persist from ongoing losses and competitive pressures. The stock's near-term direction hinges on achieving profitability and sustaining revenue growth amid high operational costs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Archer-Daniels-Midland Co
Archer-Daniels Midland is a major processor of oilseeds, corn, wheat, and other agricultural commodities. Additionally, the company owns an extensive network of logistical assets to store and transport crops around the globe. ADM also runs a nutrition business that focuses on both human and animal ingredients. The company is also a large producer of corn-based sweeteners, starches, and ethanol.
Read more on ADM →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
